A copper IUD that doesn't increase blood loss is a genuine advance
In the quiet work of clinical science, twenty-nine women in the Dominican Republic lent their bodies to a question that matters for millions: can contraception be made safer for those it most often fails? A new copper IUD combined with low-dose ulipristal acetate showed early promise in reducing menstrual bleeding without disrupting hormones or causing harm — a modest but meaningful step toward expanding reproductive options for women living with anemia.
- Copper IUDs, long valued for their reliability and hormone-free design, carry a hidden cost: they increase menstrual bleeding, making them dangerous for women already weakened by anemia.
- Researchers combined the copper IUD with ulipristal acetate — a progesterone modulator used at far higher doses for other conditions — to test whether a localized, smaller dose could neutralize that bleeding risk.
- Twenty-nine sterilized volunteers in the Dominican Republic tracked their cycles for months, submitted to biopsies and blood tests, and returned data showing reduced bleeding volume, fewer bleeding days, and no serious adverse effects.
- Ovulation remained normal, liver function was unaffected, and no participant developed anemia — early signals that the device may be both safe and effective at this dose.
- The road to clinical use is still long: Phase 2 and 3 trials lie ahead, and a European regulatory review of ulipristal at higher doses adds uncertainty, even as researchers stress the IUD delivers doses 100 times smaller.
Twenty-nine women in the Dominican Republic volunteered to test a new contraceptive device — a copper IUD embedded with low-dose ulipristal acetate — keeping detailed bleeding diaries for months before and after insertion. Their participation addressed a stubborn problem: copper IUDs are safe and effective, but they increase menstrual bleeding, making them a poor or even harmful choice for women already living with anemia.
Ulipristal acetate works by modulating the body's response to progesterone. It's used elsewhere as an emergency contraceptive and fibroid treatment, but always at much higher doses. The researchers wanted to know whether a smaller, localized amount could reduce the bleeding copper IUDs typically cause — without creating new risks.
The results, published in the journal Contraception, were encouraging. Participants showed reduced bleeding volume and fewer bleeding days. Hormones remained stable, ovulation continued normally, liver function was unaffected, and no one developed anemia. The women reported satisfaction with the device.
Lead researcher Carolina Sales Vieira of the University of São Paulo highlighted the particular importance of this advance in regions where anemia is widespread. She also raised the possibility that future studies could explore the device's potential for women with conditions like uterine fibroids that already cause heavy bleeding.
Still, the path to real-world use is long. Phase 2 trials will compare the device against conventional copper IUDs; Phase 3 will test its contraceptive efficacy. A European Medicines Agency review of ulipristal's safety — prompted by liver damage cases at much higher fibroid-treatment doses — adds regulatory complexity, even though the IUD delivers doses 100 times smaller. For now, the device remains a carefully evidenced promise, not yet a product.
Twenty-nine women in the Dominican Republic volunteered for something most would avoid: having a new contraceptive device inserted into their uterus, then keeping meticulous records of their bleeding and cramps for months. What they helped test could reshape options for millions of women who currently have none.
The device is a copper intrauterine device—an IUD—combined with a medication called ulipristal acetate. Copper IUDs have been around for decades and work well. They're safe, effective, and don't require daily pills. But they have a significant drawback: they increase menstrual bleeding. For women already struggling with anemia, this can be a serious problem. A conventional copper IUD might actually worsen their condition, making it an unsuitable choice precisely when they need contraception most.
Ulipristal works by modulating how the body's progesterone hormone functions. It's already used in other contexts—as an emergency contraceptive pill and to treat uterine fibroids—but always at much higher doses than what this new IUD would deliver. The researchers wanted to know if a smaller, localized dose could reduce the bleeding that copper IUDs typically cause, without introducing new safety problems.
The trial followed a careful protocol. The 29 participants, all from the Dominican Republic and all surgically sterilized (since this early phase wasn't yet testing pregnancy prevention), kept bleeding diaries for a month before insertion, three months after, and two months after removal. They underwent uterine biopsies, blood tests to check for hormonal changes and ovulation, and liver function tests. The results, published in the journal Contraception, showed what the researchers hoped to find: reduced bleeding volume and fewer bleeding days, with no serious side effects. The women maintained normal ovulation, their hormones stayed stable, their livers showed no damage, and none developed anemia. They reported satisfaction with the device.
Carolina Sales Vieira, a professor at the University of São Paulo's medical school and one of the study's lead authors, emphasizes why this matters. In regions where anemia is common, offering a copper IUD that doesn't increase blood loss is a genuine advance in women's health. She notes that future studies might even test whether this device could help women with conditions that already cause heavy menstrual bleeding, such as uterine fibroids.
But the path to actual use remains long. The device must still pass Phase 2 and Phase 3 trials. Phase 2 will compare it directly against conventional copper IUDs. Phase 3 will measure how well it actually prevents pregnancy—the ultimate test of any contraceptive. There's also a complication: the European Medicines Agency is currently reviewing ulipristal's safety after some cases of liver damage were reported in women taking it at much higher doses for fibroid treatment. Vieira is careful to note that the doses used in this IUD are 100 times smaller than those used for fibroids, and her team found no liver problems. Still, regulatory clarity will matter before broader testing can proceed.
The research was led by Vieira and Vivian Brache from the Dominican Republic's Biomédicas de Profamilia, with support from the U.S. National Institutes of Health and the Population Council. It represents the kind of unglamorous, methodical work that expands the toolkit available to women and their doctors. For now, it remains a promise—but one backed by careful evidence.
Notable Quotes
If we provide a copper IUD that is safe and effective but doesn't increase blood loss, we're contributing to women's health— Carolina Sales Vieira, University of São Paulo medical school
The volunteers had no serious side effects, showed reduced bleeding, maintained ovulation, and their hormones were not altered— Carolina Sales Vieira
The Hearth Conversation Another angle on the story
Why does a copper IUD cause more bleeding in the first place?
Copper itself triggers an inflammatory response in the uterus. It's actually what makes the device effective as contraception—that inflammation is hostile to sperm. But the same mechanism increases menstrual flow. It's a trade-off that works for many women, but not for those already losing too much blood.
And ulipristal solves this how?
It doesn't stop the copper from working. Instead, it modulates progesterone signaling in the uterine lining. Progesterone normally thickens the endometrium during a cycle. By adjusting how that hormone works locally, the medication appears to reduce how much tissue is shed during menstruation.
Why test it in the Dominican Republic specifically?
Anemia is more prevalent there than in wealthier countries. The researchers wanted to study the device where it would have the most immediate impact—where women actually face the choice between no contraception or a method that worsens their health.
The women were all sterilized. Doesn't that limit what you can learn?
Absolutely. It's why Phase 1 exists. You test safety and basic function first, in a controlled group. Once you know the device doesn't cause liver damage or hormonal chaos, you move to Phase 2 and 3 with women who could actually become pregnant. That's when you measure real contraceptive failure rates.
What's the European review about?
Ulipristal at high doses—100 times higher than in this IUD—caused liver problems in some women taking it for fibroids. Regulators are being cautious. But the researchers are right that dose matters enormously. A localized, low-dose delivery is a different safety profile entirely.
How long until women can actually use this?
Years, probably. Two more phases of trials, regulatory review, manufacturing scale-up. But the fact that Phase 1 worked cleanly—no serious side effects, reduced bleeding, normal hormones—means the concept is sound. It's worth the wait.